Ab Science Aktie - 0Q77

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

3,835

Gebot

3,74

Fragen

3,93

Volumen

160

0,00 Tagesbereich 0,00

3,835 52-Wochen-Bereich 3,835

Marktkapitalisierung

178,719M

Handelsende

3,835

Handelsbeginn

Letzte Trade

1.45

(O)

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

199

Ausgegebene Aktien

46.602.000

Dividendenrendite

Kurs-Gewinn-Verhältnis

-5,64

Gewinn pro Aktie (EPS)

-0,26

Erlöse

970k

Nettogewinn

-11,99M

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Preparations

Website

www.ab-science.com

Hauptsitz

Paris, Paris, Fra

Gegründet

Ab Science Sa is listed in the Pharmaceutical Preparations sector of the Londoner Börse with ticker 0Q77. The last closing price for Ab Science was 3,84 €. Over the last year, Ab Science shares have traded in a share price range of 3,835 € to 3,835 €.

Ab Science currently has 46.602.000 shares in issue. The market capitalisation of Ab Science is 178,72 € million. Ab Science has a price to earnings ratio (PE ratio) of -5.64.

La molécule AB8939 obtient la désignation de médicament orphelin auprès de l'EMA dans le traitement de la leucémie myéloïde aigue

La molécule AB8939 obtient la désignation de médicament orphelin auprès de l'EMA dans le traitement de la leucémie myéloïde aigue COMMUNIQUE...

AB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia

AB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia PRESS RELEASE EUROPEAN MEDICINES...

AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell disease

AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell disease PRESS...

AB Science reçoit un avis d’acceptation pour le brevet américain courant jusqu’en 2040 le masitinib dans le traitement de la drépanocytose

AB Science reçoit un avis d’acceptation pour le brevet américain courant jusqu’en 2040 le masitinib dans le traitement de la drépanocytose...

AB Science: Article from the leading publication Life Sciences Magazine featuring masitinib and its Phase 3 principal investigator, the neurologist Patrick Vermersch

AB Science: Article from the leading publication Life Sciences Magazine featuring masitinib and its Phase 3 principal investigator, the...

AB Science : Un article de la revue de référence Life Sciences Magazine présente le masitinib et son investigateur principal de Phase 3, le neurologue Patrick Vermersch

AB Science : Un article de la revue de référence Life Sciences Magazine présente le masitinib et son investigateur principal de Phase 3, le...

Zeitraum †	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	3.835	3.835	3.835	26	3.835	DE
4	3.835	3.835	3.835	50	3.835	DE
12	3.835	3.835	3.835	199	3.835	DE
26	3.835	3.835	3.835	2431	3.835	DE
52	3.835	3.835	3.835	1614	3.835	DE
156	3.835	3.835	3.835	4611	3.835	DE
260	3.835	3.835	3.835	4572	3.835	DE

0Q77 - Frequently Asked Questions (FAQ)

What is the current Ab Science share price?

The current share price of Ab Science is 3,835 €

How many Ab Science shares are in issue?

Ab Science has 46.602.000 shares in issue

What is the market cap of Ab Science?

The market capitalisation of Ab Science is EUR 178,72M

What is the 1 year trading range for Ab Science share price?

Ab Science has traded in the range of 3,835 € to 3,835 € during the past year

What is the PE ratio of Ab Science?

The price to earnings ratio of Ab Science is -5,64

What is the cash to sales ratio of Ab Science?

The cash to sales ratio of Ab Science is 69,71

What is the reporting currency for Ab Science?

Ab Science reports financial results in EUR

What is the latest annual turnover for Ab Science?

The latest annual turnover of Ab Science is EUR 970k

What is the latest annual profit for Ab Science?

The latest annual profit of Ab Science is EUR -11,99M

What is the registered address of Ab Science?

The registered address for Ab Science is 3 AVENUE GEORGE V, PARIS, PARIS, 75008

What is the Ab Science website address?

The website address for Ab Science is www.ab-science.com

Which industry sector does Ab Science operate in?

Ab Science operates in the PHARMACEUTICAL PREPARATIONS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
XTRXtract Resources Plc	1,025p (28,13%)	39,59M
KP2Kore Potash Plc	2,85p (23,91%)	5,65M
CRTXCrism Therapeutics Corporation	13,00p (23,81%)	256,38k
TYMTertiary Minerals Plc	0,055p (22,22%)	49,82M
NTQEnteq Technologies Plc	0,425p (21,43%)	1,04M
ELEGElectric Guitar Plc	0,0475p (-20,83%)	4M
TOMTomco Energy Plc	0,045p (-18,18%)	25,63M
PFCPetrofac Limited	4,99p (-16,83%)	5,83M
CHFChesterfield Resources Plc	0,725p (-14,71%)	1,27M
MTCMothercare Plc	2,00p (-13,79%)	1,2M
CHPCaledonian Holdings Plc	0,00475p (-5,00%)	1,34B
SYMESupply@me Capital Plc	0,0034p (17,24%)	947,05M
PREMPremier African Minerals Limited	0,0375p (-3,60%)	736,59M
VRSVersarien Plc	0,042p (-2,33%)	434,3M
ENETEthernity Networks Ltd	0,03p (-7,69%)	377,23M

Rendering Error

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Ab Science Sa (0Q77) Börsenkurse

Ab Science Sa (0Q77)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Ab Science Sa

0Q77 Neueste Nachrichten

La molécule AB8939 obtient la désignation de médicament orphelin auprès de l'EMA dans le traitement de la leucémie myéloïde aigue

AB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia

AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell disease

AB Science reçoit un avis d’acceptation pour le brevet américain courant jusqu’en 2040 le masitinib dans le traitement de la drépanocytose

AB Science: Article from the leading publication Life Sciences Magazine featuring masitinib and its Phase 3 principal investigator, the neurologist Patrick Vermersch

AB Science : Un article de la revue de référence Life Sciences Magazine présente le masitinib et son investigateur principal de Phase 3, le neurologue Patrick Vermersch

AB Science fait aujourd'hui le point sur la plateforme masitinib

AB Science today provides an update on its masitinib platform

AB Science tiendra une conférence virtuelle le mardi 28 janvier 2025, de 17h30 à 18h45

AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET

La molécule AB8939 obtient la désignation de médicament orphelin auprès de l'EMA dans le traitement de la leucémie myéloïde aigue

AB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia

AB Science reçoit un avis d’acceptation pour le brevet américain courant jusqu’en 2040 le masitinib dans le traitement de la drépanocytose

AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell disease

AB Science: Article from the leading publication Life Sciences Magazine featuring masitinib and its Phase 3 principal investigator, the neurologist Patrick Vermersch

AB Science : Un article de la revue de référence Life Sciences Magazine présente le masitinib et son investigateur principal de Phase 3, le neurologue Patrick Vermersch

AB Science today provides an update on its masitinib platform

AB Science fait aujourd'hui le point sur la plateforme masitinib

0Q77 - Frequently Asked Questions (FAQ)

Beweger

0Q77 Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Registrieren Sie sich für ein Konto unter ADVFN

Werbung entfernen